KOSDAQBiotech & Pharma044960

Eagle Veterinary Technology

₩2,820▼ 0.53%2026-11-18 close
Market Cap
₩35.7B
Turnover
₩30,501,080
Volume
10K
Shares out.
12.6M
PER
7.7×
PBR
0.7×
EPS
₩373
Dividend Yield
2.80%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩80 per share · Prices as of the 2026-11-18 close

01

Report overview

Profit Recovery Met a Q3 2026 Loss; Durability Is the Test

Controlling-shareholder net income rose for three straight years through 2025 and the operating margin reached 9.8%, but Q3 2026 brought a controlling-shareholder net loss of KRW 323 million, making profit durability the next point to watch.

  1. 1

    Operating profit reached KRW 4.26 billion in 2025, up 22.9% year on year, and the 9.8% operating margin was the highest of 2022 to 2025.

  2. 2

    In Q3 2026, sales were KRW 10.7 billion and operating profit KRW 854 million, both below the prior quarter, and the company swung to a controlling-shareholder net loss of KRW 323 million from a year earlier.

  3. 3

    The debt ratio (total liabilities to total equity) fell from 27.7% in 2022 to 23.3% in 2025, with total equity of KRW 51.9 billion and total liabilities of KRW 12.1 billion at year-end 2025.

  4. 4

    The company is pushing new ventures in pet medicines, pet feed and non-drug products, and the revenue contribution of these ventures can be gauged from segment information in the next annual report.

  5. 5

    Whether the Q3 2026 swing to a loss is temporary will show up in full-year 2026 figures in the annual report, which is due by the end of March 2027.

02

Business structure

Eagle Veterinary Technology was founded in December 1983 and its core business is manufacturing and importing veterinary medicines.

It holds KVGMP certification for injectables, liquids and additives, and an investment information service describes that certification and market trust as the basis of its export capability.

In November 2017 it became the first domestic veterinary drug maker to obtain EU GMP certification for a sterile injectable production facility, according to a March 2021 brokerage report. The company also runs a pet business and is pushing new ventures in pet medicines, pet feed and non-drug products.

A 2018 equity research report estimated that pet feed and feed additives made up more than 70% of sales at that time, so the current segment mix may differ. On distribution, the 2021 report described new direct channels with Coupang and GS SHOP and a push for mid- to low-priced private-label products.

In competition, large corporates such as Lotte were launching pet brands as of 2018. Headcount was 112 as of June 30, 2026, according to JobKorea. The largest shareholder group held 38.40% as of September 2025. Updated segment sales mix will be reflected in the next annual report.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩10.5B₩300M2.7%
2025Q4₩11.1B₩1.1B9.7%
2026Q1₩11B₩1.4B12.4%
2026Q2₩12.1B₩1.7B14.4%
2026Q3₩10.7B₩900M8.0%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩43.5B₩3.6B₩2.6B8.2%6.2%27.7%
2023₩42.8B₩3.3B₩3B7.8%6.6%29.0%
2024₩41.7B₩3.5B₩3.7B8.3%7.6%26.0%
2025₩43.3B₩4.3B₩3.9B9.8%7.6%23.3%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual revenue declined from 435 hundred million won in 2022 to 428 hundred million won in 2023 (down 1.7% year over year) and 417 hundred million won in 2024 (down 2.5% year over year), then recovered to 433 hundred million won in 2025 (up 3.9% year over year).

Over 2022-2025, the year with the highest revenue was 2022 and the year with the lowest was 2024.

Operating profit bottomed at 33.3 hundred million won in 2023 (down 6.5% year over year), then rose to 34.7 hundred million won in 2024 (up 4.3% year over year) and 42.6 hundred million won in 2025 (up 22.9% year over year), increasing for two consecutive years from 2024 to 2025.

Over 2022-2025, the year with the highest operating profit was 2025. The operating margin was 8.2% in 2022, 7.8% in 2023, 8.3% in 2024, and 9.8% in 2025, with 2025 the highest. While revenue grew 3.9%, operating profit grew 22.9%, so margin improvement drove the profit increase more strongly.

Net profit attributable to controlling shareholders rose from 26.4 hundred million won in 2022 to 29.8 hundred million won in 2023 (up 12.6% year over year), 37.1 hundred million won in 2024 (up 24.5% year over year), and 39.5 hundred million won in 2025 (up 6.5% year over year), increasing for three consecutive years from 2023 to 2025.

Net profit including non-controlling interests was also reported as 26.4 hundred million won, 29.8 hundred million won, 37.1 hundred million won, and 39.5 hundred million won for the same years, the same values as net profit attributable to controlling shareholders.

Operating cash flow was -3.2 hundred million won in 2022, then 48.9 hundred million won in 2023, 43.4 hundred million won in 2024, and 55.1 hundred million won in 2025, positive in all three years since 2023.

On a quarterly basis, results improved from revenue of 105 hundred million won and operating profit of 2.9 hundred million won in the third quarter of 2025 to revenue of 111 hundred million won and operating profit of 10.8 hundred million won in the fourth quarter of 2025 (up 278.3% quarter over quarter).

The profit trend continued with revenue of 110 hundred million won and operating profit of 13.7 hundred million won in the first quarter of 2026, and revenue of 121 hundred million won and operating profit of 17.4 hundred million won in the second quarter of 2026.

In the third quarter of 2026, revenue was only 107 hundred million won (down 12.3% quarter over quarter, up 1.8% year over year) and operating profit was only 8.5 hundred million won (down 51.0% quarter over quarter, up 198.7% year over year), and net loss attributable to controlling shareholders was 3.2 hundred million won, a swing to a loss from a year earlier.

That operating profit stayed positive while net profit attributable to controlling shareholders turned to a loss means items below operating profit pulled down the period's profit significantly.

The sum of net profit attributable to controlling shareholders over the latest four quarters (the fourth quarter of 2025 through the third quarter of 2026) is 47.1 hundred million won.

05

Industry analysis

A 2021 research report described the domestic pet market as growing rapidly, and the company's pet-related sales growth is read as tied to that expansion. Growth in livestock environments and small-animal markets is another growth driver the company cites.

However, livestock breeding supply and disease outbreaks drive demand for veterinary medicines, so the cycle position is hard to describe with figures.

The company's strength is its KVGMP certification for injectables, liquids and additives, together with an EU GMP-certified production facility, which the 2021 report cited as a basis for its competitiveness as a contract manufacturer.

On competition, a 2018 report pointed to large corporates such as Lotte launching pet brands. Compared with the distribution scale of large companies, the 2021 report said Eagle Veterinary Technology chose to widen its sales network through direct channels and mid- to low-priced private-label products.

Its pet business relied heavily on distribution of imported premium pet feed as of 2018, which exposes it to raw material prices, exchange rates and import conditions. Certification-backed export competitiveness is the central variable in the veterinary medicine segment.

06

Outlook

The new ventures under way are the manufacturing and import and sale of pet medicines, pet feed and non-drug products. Their revenue contribution can be gauged once segment information appears in disclosures.

The board decided on a year-end cash dividend on February 10, 2026, with the shareholders meeting scheduled for March 25, 2026. Q2 2026 sales of KRW 12.1 billion and operating profit of KRW 1.74 billion were followed in Q3 2026 by sales of KRW 10.7 billion and operating profit of KRW 854 million.

Quarterly momentum peaked in Q2 2026 and turned down, and whether this is seasonal or structural should be judged on full-year figures.

Supporting factors include the export certification base and new pet ventures, while the large swings in quarterly profit and the burden from items below operating profit are the negatives.

The next annual report covering 2026 is due by the end of March 2027, and it will show whether 2026 full-year sales and operating margin hold near the 9.8% of 2025. Whether the trend after Q3 2026 continues will be visible in the Q1 2027 quarterly report.

07

Valuation

PER
7.7×
PBR
0.7×
ROE
9.0%
EPS
₩373
BPS
₩4,300
Dividend per share
₩80

Valuation can be read through two lenses, net assets and earnings. Of the KRW 51.9 billion in total equity at year-end 2025, the controlling-shareholder stake is the same KRW 51.9 billion, so the share price relative to net assets is compared directly with the parent's asset value.

On earnings, the comparison base is controlling-shareholder net income of KRW 3.95 billion in 2025 and the KRW 4.71 billion total for the last four quarters. Because the Q3 2026 net loss sits inside the last four quarters total, earnings-based multiples are sensitive to quarterly swings.

Against the trend of rising operating profit and controlling-shareholder net income since 2023, the multiple reads differently depending on whether profits continue. The February 10, 2026 board decision on a year-end cash dividend is a reference point for shareholder returns.

Comparisons with listed peers in the same industry are limited because business structures differ widely. The key to reading the multiple is whether the Q3 2026 loss proves temporary in full-year 2026 results.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Earnings recovery

Controlling-shareholder net income rose three years in a row from 2023 through 2025, and operating profit rose two years in a row from 2024 through 2025. The operating margin of 9.8% in 2025 was the highest of 2022 to 2025. Operating profit of KRW 4.26 billion in 2025 was above the KRW 3.56 billion of 2022. The fact that profit improvement outpaced sales recovery is the bullish point here.

Financial headroom

The debt ratio fell from 27.7% in 2022 to 23.3% in 2025. Total equity at year-end 2025 was KRW 51.9 billion and total liabilities were KRW 12.1 billion. The controlling-shareholder stake accounts for all of the KRW 51.9 billion of equity. A balance sheet with a light debt burden reads as headroom to absorb business swings.

Positive operating cash flow

Operating cash flow swung from a KRW 318 million deficit in 2022 to KRW 4.89 billion in 2023, then stayed positive at KRW 4.34 billion in 2024 and KRW 5.51 billion in 2025. The 2025 operating cash flow exceeded that year's operating profit of KRW 4.26 billion.

Cash generation that holds alongside profit can serve as a funding source for dividends and business investment.

09

Bear factors

Q3 2026 swing to loss

The controlling-shareholder result in Q3 2026 swung to a net loss of KRW 323 million from a year earlier. Operating profit in the same quarter of KRW 854 million fell 51.0% from the prior quarter. Compared with Q2 2026 operating profit of KRW 1.74 billion, the quarterly peak was short-lived, which is the bearish point. The Q3 loss is also included in the four-quarter total of KRW 4.71 billion, which weighs on that figure.

Stalled sales

Sales went from KRW 43.5 billion in 2022 to KRW 43.3 billion in 2025, roughly flat over the period. Sales declined in 2023 and 2024, and the 3.9% rise in 2025 was a recovery after those years. Q3 2026 sales of KRW 10.7 billion rose only 1.8% from a year earlier. Limited top-line growth means profit gains have come mainly from profitability.

Small-cap size and concentrated ownership

The company is a small cap with a market value of about KRW 36.2 billion. The largest shareholder group's stake accounts for a sizable part of the shares, which affects the float. A high concentration like this can limit the float available for trading. Smaller companies can see sharp share-price reactions to earnings swings, which is another bearish factor.

10

Risk factors

Earnings volatility

Quarterly operating profit moved sharply, from KRW 286 million in Q3 2025 to KRW 1.08 billion in Q4 2025 and KRW 1.74 billion in Q2 2026. It fell to KRW 854 million in Q3 2026 and the controlling-shareholder result turned to a loss. Large quarterly swings reduce confidence in full-year outlooks. Items below operating profit also move the quarterly result.

Business mix and competition

A 2018 report estimated that pet feed and feed additives made up more than 70% of sales at that time. A business built on imported premium pet feed is sensitive to raw material prices, exchange rates and import conditions. Entry by large corporates such as Lotte intensifies distribution competition. How far the new ventures will change this mix is not yet visible in disclosed figures.

Certification and production regulation

KVGMP certification for injectables, liquids and additives, together with the EU GMP-certified facility, underpins exports and contract manufacturing. Any problem in maintaining or renewing certification could directly affect production and exports.

Pharmaceutical manufacturing regulation also raises quality-control costs. Changes to this base feed directly into export sales and margins.

11

What to watch next

  1. End of December 2026

    This is the close of fiscal year 2026. The checkpoints are whether the full-year 2026 operating margin holds near the 9.8% of 2025 and whether the Q3 2026 loss drivers persist through year-end.

  2. End of March 2027

    This is the filing deadline for the 2026 annual report. Segment sales, full-year controlling-shareholder net income, changes in equity and the contribution of the new pet ventures are expected to appear in disclosed figures.

  3. Mid-May 2027

    This is the filing deadline for the Q1 2027 quarterly report. The checkpoints are whether the loss from Q3 2026 continues and whether operating profit recovery holds.

12

Overall view

Eagle Veterinary Technology's sales were roughly flat, at KRW 43.5 billion in 2022 and KRW 43.3 billion in 2025, but operating profit reached KRW 4.26 billion in 2025, the largest of 2022 to 2025, and the operating margin rose to 9.8%.

Controlling-shareholder net income increased three years in a row from 2023 through 2025, and operating cash flow stayed positive over the same period. The balance sheet shows a debt ratio of 23.3% and total liabilities of KRW 12.1 billion.

In Q3 2026, however, sales fell 12.3% from the prior quarter and operating profit declined, and the controlling-shareholder result turned to a net loss of KRW 323 million. Controlling-shareholder net income for the last four quarters totaled KRW 4.71 billion, so the recovery is clear but quarterly swings are large.

On the business side, KVGMP and EU GMP-backed production underpins exports and contract manufacturing, and how far the new pet ventures change the revenue mix is the next question.

The next checkpoints are full-year 2026 results, segment information in the 2026 annual report, and whether the Q3 2026 loss continues in the Q1 2027 quarterly report. This report is provided for information only and does not state an investment opinion, rating or target price.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. comp.fnguide.com
  2. ssl.pstatic.net
  3. kr.tradingview.com
  4. stockvery.com
  5. news.nate.com
  6. edaily.co.kr
  7. researcharum.com
  8. jobkorea.co.kr
  9. jobkorea.co.kr
  10. kind.krx.co.kr
  11. cmelitegroup.com
  12. investing.com
  13. kind.krx.co.kr
  14. judal.co.kr
  15. chaincatcher.com
  16. judal.co.kr
  17. judal.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis